Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis

Clinical and Experimental Immunology

Volumn 159, Issue 3, 2010, Pages 303-314

  Copland, D A ^a   Hussain, K ^a   Baalasubramanian, S ^b   Hughes, T R ^b   Morgan, B P ^b   Xu, H ^c   Dick, A D ^a   Nicholson, L B ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Autoimmunity; Complement C5; Experimental autoimmune uveoretinitis; Macrophage activation; Therapy

Indexed keywords

COMPLEMENT COMPONENT C5 INHIBITOR; GAMMA INTERFERON; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT; UVEORETINITIS;

ANAPHYLATOXINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; AUTOIMMUNE DISEASES; COMPLEMENT ACTIVATION; COMPLEMENT C5; COMPLEMENT MEMBRANE ATTACK COMPLEX; DISEASE MODELS, ANIMAL; INFLAMMATION; INTERFERON-GAMMA; MICE; NITRIC OXIDE; RATS; RETINITIS; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; UVEITIS;

EID: 74549136857     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04070.x     Document Type: Article

References (61)

1. Forrester JV, Liversidge J, Dua HS, Towler H, McMenamin PG. Comparison of clinical and experimental uveitis. Curr Eye Res 1990 9 (Suppl 75 84.
2. Dick AD. Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis? Br J Ophthalmol 1995 79 : 81 8.
3. Kerr EC, Copland DA, Dick AD, Nicholson LB. The dynamics of leukocyte infiltration in experimental autoimmune uveoretinitis. Prog Retin Eye Res 2008 27 : 527 535.
4. Caspi RR. Regulation, counter-regulation, and immunotherapy of autoimmune responses to immunologically privileged retinal antigens. Immunol Res 2003 27 : 149 160.
5. de Smet MD, Chan CC. Regulation of ocular inflammation - what experimental and human studies have taught us. Prog Retin Eye Res 2001 20 : 761 797.
6. Wacker WB. Retinal autoimmunity: two decades of research. Jpn J Ophthalmol 1987 31 : 188 196.
7. Wacker WB. Proctor lecture. Experimental allergic uveitis. Investigations of retinal autoimmunity and the immunopathologic responses evoked. Invest Ophthalmol Vis Sci 1991 32 : 3119 3128.
8. Atalla L, Linker-Israeli M, Steinman L, Rao NA. Inhibition of autoimmune uveitis by anti-CD4 antibody. Invest Ophthalmol Vis Sci 1990 31 : 1264 1270. (Pubitemid 20212354)
9. Caspi RR. Immunogenetic aspects of clinical and experimental uveitis. Reg Immunol 1992 4 : 321 330.
10. Thurau SR, Chan CC, Nussenblatt RB, Caspi RR. Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals. Clin Exp Immunol 1997 109 : 370 376.
11. Hoey S, Grabowski PS, Ralston SH, Forrester JV, Liversidge J. Nitric oxide accelerates the onset and increases the severity of experimental autoimmune uveoretinitis through an IFN-gamma-dependent mechanism. J Immunol 1997 159 : 5132 5142.
12. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 2002 111 : 927 930.
13. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003 3 : 23 35.
14. Forrester JV, Huitinga I, Lumsden L, Dijkstra CD. Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats. Curr Eye Res 1998 17 : 426 437.
15. Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun 1998 11 : 255 264.
16. Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 2004 23 : 617 637.
17. Copland DA, Calder CJ, Raveney BJ et al. Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am J Pathol 2007 171 : 580 588.
18. Walport MJ. Complement. First of two parts. N Engl J Med 2001 344 : 1058.
19. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004 5 : 981 986.
20. Sohn JH, Bora PS, Suk HJ, Molina H, Kaplan HJ, Bora NS. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat Med 2003 9 : 206 212.
21. Linton SM, Morgan BP. Complement activation and inhibition in experimental models of arthritis. Mol Immunol 1999 36 : 905 914.
22. Woodruff TM, Strachan AJ, Dryburgh N et al. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum 2002 46 : 2476 2485.
23. Prineas JW, Kwon EE, Cho ES et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001 50 : 646 657.
24. Morgan BP, Griffiths M, Khanom H, Taylor SM, Neal JW. Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats. Clin Exp Immunol 2004 138 : 430 438.
25. Kijlstra A, La Heij E, Hendrikse F. Immunological factors in the pathogenesis and treatment of age-related macular degeneration. Ocul Immunol Inflamm 2005 13 : 3 11.
26. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 2000 14 : 835 846.
27. Nozaki M, Raisler BJ, Sakurai E et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 2006 103 : 2328 2333.
28. Jha P, Bora PS, Bora NS. The role of complement system in ocular diseases including uveitis and macular degeneration. Mol Immunol 2007 44 : 3901 3908.
29. Montalvo V, Campos MM, Chan CC et al. Complement deposits on ocular tissues adjacent to sites of inflammation. Curr Eye Res 2007 32 : 917 922.
30. Read RW, Szalai AJ, Vogt SD, McGwin G, Barnum SR. Genetic deficiency of C3 as well as CNS-targeted expression of the complement inhibitor sCrry ameliorates experimental autoimmune uveoretinitis. Exp Eye Res 2006 82 : 389 394.
31. Jha P, Sohn JH, Xu Q et al. The complement system plays a critical role in the development of experimental autoimmune anterior uveitis. Invest Ophthalmol Vis Sci 2006 47 : 1030 1038.
32. Jha P, Sohn JH, Xu Q et al. Suppression of complement regulatory proteins (CRPs) exacerbates experimental autoimmune anterior uveitis (EAAU). J Immunol 2006 176 : 7221 7231.
33. An F, Li Q, Tu Z et al. Role of DAF in protecting against T-cell autoreactivity that leads to experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2009 50 : 3778 3782.
34. Turnberg D, Botto M. The regulation of the complement system: insights from genetically-engineered mice. Mol Immunol 2003 40 : 145 153.
35. Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991 349 : 614 617.
36. Monk PN, Scola AM, Madala P, Fairlie DP. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 2007 152 : 429 448.
37. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995 92 : 8955 8959.
38. Frei Y, Lambris JD, Stockinger B. Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies. Mol Cell Probes 1987 1 : 141 149.
39. Dick AD, Cheng YF, Liversidge J, Forrester JV. Immunomodulation of experimental autoimmune uveoretinitis: a model of tolerance induction with retinal antigens. Eye 1994 8 : 52 9.
40. Paques M, Guyomard JL, Simonutti M et al. Panretinal, high-resolution color photography of the mouse fundus. Invest Ophthalmol Vis Sci 2007 48 : 2769 2774.
41. Copland DA, Wertheim MS, Armitage J, Nicholson LB, Raveney BJ, Dick AD. The clinical time-course of experimental autoimmune uveoretinitis using topical endoscopic fundal imaging with histological and cellular infiltrate correlation. Invest Ophthalmol Vis Sci 2008 49 : 5458 5465.
42. Holt DS, Botto M, Bygrave AE, Hanna SM, Walport MJ, Morgan BP. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 2001 98 : 442 449.
43. Munder M, Eichmann K, Moran JM, Centeno F, Soler G, Modolell M. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 1999 163 : 3771 3777.
44. Kerr EC, Raveney BJ, Copland DA, Dick AD, Nicholson LB. Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. J Autoimmun 2008 31 : 354 361.
45. Liu J, Lin F, Strainic MG et al. IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. J Immunol 2008 180 : 5882 5889.
46. Strainic MG, Liu J, Huang D et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008 28 : 425 435.
47. Manthey HD, Woodruff TM, Taylor SM, Monk PN. Complement component 5a (C5a). Int J Biochem Cell Biol 2009 41 : 2114 2117.
48. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol 2005 23 : 821 852.
49. Cavaillon JM, Fitting C, Haeffner-Cavaillon N. Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 1990 20 : 253 257.
50. Scholz W, McClurg MR, Cardenas GJ et al. C5a-mediated release of interleukin 6 by human monocytes. Clin Immunol Immunopathol 1990 57 : 297 307.
51. Ember JA, Sanderson SD, Hugli TE, Morgan EL. Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin. Am J Pathol 1994 144 : 393 403.
52. Kunkel SL, Kaercher K, Plewa M, Fantone JC, Ward PA. Production of cyclooxygenase products and superoxide anion by macrophages in response to chemotactic factors. Prostaglandins 1982 24 : 789 799.
53. Rabiet MJ, Huet E, Boulay F. Complement component 5a receptor oligomerization and homologous receptor down-regulation. J Biol Chem 2008 283 : 31038 31046.
54. Xu H, Koch P, Chen M, Lau A, Reid DM, Forrester JV. A clinical grading system for retinal inflammation in the chronic model of experimental autoimmune uveoretinitis using digital fundus images. Exp Eye Res 2008 87 : 319 326.
55. Dick AD, Carter D, Robertson M et al. Control of myeloid activity during retinal inflammation. J Leukoc Biol 2003 74 : 161 166.
56. Robertson MJ, Erwig LP, Liversidge J, Forrester JV, Rees AJ, Dick AD. Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis. Invest Ophthalmol Vis Sci 2002 43 : 2250 2257.
57. Broderick C, Duncan L, Taylor N, Dick AD. IFN-gamma and LPS-mediated IL-10-dependent suppression of retinal microglial activation. Invest Ophthalmol Vis Sci 2000 41 : 2613 2622.
58. van der Veen RC, Dietlin TA, Dixon Gray J, Gilmore W. Macrophage-derived nitric oxide inhibits the proliferation of activated T helper cells and is induced during antigenic stimulation of resting T cells. Cell Immunol 2000 199 : 43 9.
59. Raveney BJ, Copland DA, Dick AD, Nicholson LB. TNFR1-dependent regulation of myeloid cell function in experimental autoimmune uveoretinitis. J Immunol 2009 183 : 2321 2329.
60. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007 25 : 1265 1275.
61. Peng Q, Li K, Patel H, Sacks SH, Zhou W. Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol 2006 176 : 3330 3341.